Fig. 3: Effective inhibition of JAK2V617F-induced MPN mouse model in vivo by FM.
BALB/c-nude mice received intravenous inoculation of 3.0 × 106 Ba/F3-JAK2V617F-GFP cells and were administered with the vehicle, FM 15 and 30 mg/kg, and fedratinib 30 mg/kg bid. p.o. after 3 days, and the mice were executed after 22 days of treatment. A Kaplan–Meier analysis of survival between the vehicle-, FM- and fedratinib-treated groups was performed using the log-rank test (n = 7). B Spleens were acquired and analyzed (n = 6). C Western blot analysis of phosphorylated STAT3/5 and total STAT3/5 levels in spleens (n = 3). D Representative histological sections of the spleen and liver sections and the extent of myelo-erythroid infiltration were stained with H&E, and the expression of p-JAK2 in the spleen was assayed via IHC staining. White pulp (yellow arrow), red pulp (green arrow), and tumor cell infiltration (red arrow) were marked. Images were obtained at ×100 and ×400 magnification. The histogram on the right panel is the quantitative statistics of IHC staining results performed by Image-Pro Plus. Data are represented as mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001 vs. vehicle, t-test.
